Efficacy, safety and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
CONCLUSIONS: 48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.PMID:38190830 | DOI:10.3350/cmh.2023.0422 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 8, 2024 Category: Gastroenterology Authors: Jinlin Hou Edward Gane Rozalina Balabanska Wenhong Zhang Jiming Zhang Tien Huey Lim Qing Xie Chau-Ting Yeh Sheng-Shun Yang Xieer Liang Piyawat Komolmit Apinya Leerapun Zenghui Xue Ethan Chen Yuchen Zhang Qiaoqiao Xie Ting-Tsung Chang Tsung-Hui Hu Seng Gee Source Type: research
Comprehensive Approach to Controlling Chronic Hepatitis B in China
Clin Mol Hepatol. 2024 Jan 5. doi: 10.3350/cmh.2023.0412. Online ahead of print.ABSTRACTHepatitis B virus (HBV) infection was highly endemic in China, where the prevalence of HBsAg was 9.7% in 1992. Comprehensive strategies, including universal infant hepatitis B vaccination with emphasis on timely birth-dose and 3-dose coverage, dramatically reduced the mother-to-infant transmission and early childhood acquisition of HBV, resulting in estimated HBsAg prevalence rates of 5.6% and 0.1% in the general population and among children aged <5 years in 2022, respectively. Clinical guidelines on the prevention and treatment of ...
Source: Clinical and molecular hepatology - January 4, 2024 Category: Gastroenterology Authors: Shan Shan Xinyan Zhao Jidong Jia Source Type: research
Evaluating the Therapeutic Efficacy of NAD Supplementation in Management of MASLD: Key Considerations
Clin Mol Hepatol. 2023 Dec 29. doi: 10.3350/cmh.2023.0555. Online ahead of print.NO ABSTRACTPMID:38163440 | DOI:10.3350/cmh.2023.0555 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 1, 2024 Category: Gastroenterology Authors: Xinyi Lu Rui Yang Yu Chen Daozhen Chen Source Type: research
Prognostic Value of Ultra-Low-Pass Whole-Genome Sequencing of Circulating Tumor DNA in hepatocellular carcinoma under systemic treatment
CONCLUSIONS: ULP-WGS of cfDNA provides clinically relevant information about the tumor biology. The presence of ctDNA and the loss of 5q and 16q arms in ctDNA-positive patients are independent predictors of worse prognosis in patients with advanced HCC under systemic therapy.PMID:38163441 | DOI:10.3350/cmh.2023.0426 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 1, 2024 Category: Gastroenterology Authors: Miguel Sogbe Idoia Bilbao Francesco P Marchese Jon Zazpe Annarosaria De Vito Marta Pozuelo Delia D'Avola Mercedes I ñarrairaegui Carmen Berasain Maria Arechederra Josepmaria Argemi Bruno Sangro Source Type: research
Evaluating the Therapeutic Efficacy of NAD Supplementation in Management of MASLD: Key Considerations
Clin Mol Hepatol. 2023 Dec 29. doi: 10.3350/cmh.2023.0555. Online ahead of print.NO ABSTRACTPMID:38163440 | DOI:10.3350/cmh.2023.0555 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 1, 2024 Category: Gastroenterology Authors: Xinyi Lu Rui Yang Yu Chen Daozhen Chen Source Type: research
Prognostic Value of Ultra-Low-Pass Whole-Genome Sequencing of Circulating Tumor DNA in hepatocellular carcinoma under systemic treatment
CONCLUSIONS: ULP-WGS of cfDNA provides clinically relevant information about the tumor biology. The presence of ctDNA and the loss of 5q and 16q arms in ctDNA-positive patients are independent predictors of worse prognosis in patients with advanced HCC under systemic therapy.PMID:38163441 | DOI:10.3350/cmh.2023.0426 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 1, 2024 Category: Gastroenterology Authors: Miguel Sogbe Idoia Bilbao Francesco P Marchese Jon Zazpe Annarosaria De Vito Marta Pozuelo Delia D'Avola Mercedes I ñarrairaegui Carmen Berasain Maria Arechederra Josepmaria Argemi Bruno Sangro Source Type: research
Evaluating the Therapeutic Efficacy of NAD Supplementation in Management of MASLD: Key Considerations
Clin Mol Hepatol. 2023 Dec 29. doi: 10.3350/cmh.2023.0555. Online ahead of print.NO ABSTRACTPMID:38163440 | DOI:10.3350/cmh.2023.0555 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 1, 2024 Category: Gastroenterology Authors: Xinyi Lu Rui Yang Yu Chen Daozhen Chen Source Type: research
Prognostic Value of Ultra-Low-Pass Whole-Genome Sequencing of Circulating Tumor DNA in hepatocellular carcinoma under systemic treatment
CONCLUSIONS: ULP-WGS of cfDNA provides clinically relevant information about the tumor biology. The presence of ctDNA and the loss of 5q and 16q arms in ctDNA-positive patients are independent predictors of worse prognosis in patients with advanced HCC under systemic therapy.PMID:38163441 | DOI:10.3350/cmh.2023.0426 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 1, 2024 Category: Gastroenterology Authors: Miguel Sogbe Idoia Bilbao Francesco P Marchese Jon Zazpe Annarosaria De Vito Marta Pozuelo Delia D'Avola Mercedes I ñarrairaegui Carmen Berasain Maria Arechederra Josepmaria Argemi Bruno Sangro Source Type: research
Hepatitis B Core-Related Antigen Dynamics and Risk of Subsequent Clinical Relapses after Nucleos(t)ide Analog Cessation
CONCLUSIONS: Dynamic measurement of HBcrAg after NA cessation is predictive of subsequent CR and may be useful to guide post-treatment monitoring.PMID:38092551 | DOI:10.3350/cmh.2023.0194 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - December 13, 2023 Category: Gastroenterology Authors: Ying-Nan Tsai Jia-Ling Wu Cheng-Hao Tseng Tzu-Haw Chen Yi-Ling Wu Chieh-Chang Chen Yu-Jen Fang Tzeng-Huey Yang Mindie H Nguyen Jaw-Town Lin Yao-Chun Hsu Source Type: research
